{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:36Z","timestamp":1792218636474,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.critrevonc.2016.11.009","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T21:31:29Z","timestamp":1479763889000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review"],"prefix":"10.1016","volume":"109","author":[{"given":"Garrett K.","family":"Berger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Royball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongseok","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Gee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz","family":"Bin Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam A.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Puvvada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.critrevonc.2016.11.009_bib0005","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1200\/JCO.2010.33.3641","article-title":"A rare case of CD30+, radiation-induced cutaneous angiosarcoma misdiagnosed as T-cell lymphoma","volume":"29","author":"Aggerholm-Pedersen","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.11.009_bib0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.coph.2004.02.007","article-title":"The role of CD30 in the pathogenesis of haematopoietic malignancies","volume":"4","author":"Al-Shamkhani","year":"2004","journal-title":"Curr. Opin. Pharmacol."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.11.009_bib0015","article-title":"Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors","volume":"31","author":"Albany","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.11.009_bib0020","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.4049\/jimmunol.157.8.3229","article-title":"CD30 expression on human CD8+ T cells isolated from peripheral blood lymphocytes of normal donors","volume":"157","author":"Argrawal","year":"1996","journal-title":"J. Immunol. (Baltimore, Md.: 1950)"},{"issue":"15","key":"10.1016\/j.critrevonc.2016.11.009_bib0025","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.1200\/jco.2009.27.15_suppl.8500","article-title":"Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL)","volume":"27","author":"Bartlett","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2016.11.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.629.629","article-title":"Brentuximab vedotin monotherapy in DLBCL patients with undetectable CD30: preliminary results from a phase 2 study","volume":"124","author":"Bartlett","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0040","first-page":"S95","article-title":"Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drugconjugate against CD30, in mycosis fungoides (MF) and S\u00e9zary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels","volume":"132","author":"Bashey","year":"2012","journal-title":"J. Invest. Dermatol."},{"issue":"26","key":"10.1016\/j.critrevonc.2016.11.009_bib0045","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2016.11.009_bib0050","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/modpathol.2011.6","article-title":"MAGEC2 is a sensitive and novel marker for seminoma: a tissue microarray analysis of 325 testicular germ cell tumors","volume":"24","author":"Bode","year":"2011","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0055","unstructured":"Brentuximab vedotin [package insert]. Seattle Genetics, I, Bothell, WA, 2011. <http:\/\/www.seattlegenetics.com\/pdf\/adcetris_USPI.pdf>(Accessed 04\/21\/2016."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.11.009_bib0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.clml.2013.03.008","article-title":"Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports","volume":"13","author":"Broccoli","year":"2013","journal-title":"Clin. Lymph. Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.11.009_bib0065","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/clim.1998.4636","article-title":"CD30 in normal and neoplastic cells","volume":"90","author":"Chiarle","year":"1999","journal-title":"Clin. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.11.009_bib0070","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/(SICI)1096-9896(200004)190:5<613::AID-PATH559>3.0.CO;2-0","article-title":"Expression of the CD30 antigen in non-lymphoid tissues and cells","volume":"190","author":"D\u00fcrkop","year":"2000","journal-title":"J. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.11.009_bib0075","first-page":"781","article-title":"Activity of brentuximab vedotin (adcetris TM) in replaced progressive CD30+ transformed mycosis fungoides (TMF)","volume":"35","author":"Devarakonda","year":"2012","journal-title":"J. Immunother."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.11.009_bib0080","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.5858\/2000-124-1077-MMWCP","article-title":"Malignant mesothelioma with CD30-positivity: a case report and review of the literature","volume":"124","author":"Dunphy","year":"2000","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2016.11.009_bib0085","doi-asserted-by":"crossref","first-page":"[45]","DOI":"10.1182\/blood.V122.21.367.367","article-title":"Phase II trial of brentuximab vedotin for CD30+ cutaneous T-Cell lymphomas and lymphoproliferative disorders","volume":"122","author":"Duvic","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.11.009_bib0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1158\/1078-0432.CCR-11-1425","article-title":"A phase I weekly dosing study of brentuximab vedotin in patients with relapsed\/refractory CD30-positive hematologic malignancies","volume":"18","author":"Fanale","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"28","key":"10.1016\/j.critrevonc.2016.11.009_bib0095","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0100","series-title":"Lymphoma, Non-Hodgkin","first-page":"716","author":"Ferri","year":"2015"},{"issue":"21","key":"10.1016\/j.critrevonc.2016.11.009_bib0105","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3096.3096","article-title":"Brentuximab vedotin (BV) plus rituximab (R) as frontline therapy for patients (pts) with epstein barr virus (EBV)+ and\/or CD30+ lymphoma: phase I results of an ongoing phase I\u2013II study","volume":"124","author":"Gandhi","year":"2014","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.critrevonc.2016.11.009_bib0110","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1046\/j.1365-2559.1998.00405.x","article-title":"A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours","volume":"32","author":"Garcia-Prats","year":"1998","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.critrevonc.2016.11.009_bib0115","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3324\/haematol.2012.069393","article-title":"Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center","volume":"98","author":"Gibb","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.11.009_bib0120","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","article-title":"Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation","volume":"120","author":"Gopal","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.11.009_bib0125","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/modpathol.2009.66","article-title":"Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3\/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas","volume":"22","author":"Gopalan","year":"2009","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0130","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2147\/OTT.S59795","article-title":"Combination therapy with brentuximab vedotin and cisplatin\/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma","volume":"7","author":"Heidegger","year":"2014","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0135","article-title":"Complete remission of CD30 positive diffuse large B-cell lymphoma (DLBCL) in a patient with post-transplant lymphoproliferative disorder (PTLD) and end-stage renal disease treated with single agent brentuximab vedotin","author":"Hill","year":"2014","journal-title":"Leukemia Lymphoma"},{"issue":"11","key":"10.1016\/j.critrevonc.2016.11.009_bib0140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/S0046-8177(96)90310-X","article-title":"CD30 expression in seminoma","volume":"27","author":"Hittmair","year":"1996","journal-title":"Hum. Pathol."},{"issue":"12","key":"10.1016\/j.critrevonc.2016.11.009_bib0145","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","article-title":"Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia","volume":"31","author":"Holderness","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.critrevonc.2016.11.009_bib0150","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.critrevonc.2016.11.009_bib0155","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.critrevonc.2016.11.009_bib0160","first-page":"29","article-title":"Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin","volume":"6","author":"Kaffenberger","year":"2013","journal-title":"J. Clin. Aesthet. Dermatol."},{"issue":"21","key":"10.1016\/j.critrevonc.2016.11.009_bib0165","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides or sezary syndrome: final results show significant clinical activity and suggest correlation with CD30 expression","volume":"124","author":"Kim","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.11.009_bib0170","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/j.1365-2559.2006.02449.x","article-title":"Expression of CD30 (Ber-H2) in nasopharyngeal carcinoma, undifferentiated type and lymphoepithelioma-like carcinoma: a comparison study with anaplastic large cell lymphoma","volume":"48","author":"Kneile","year":"2006","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.critrevonc.2016.11.009_bib0175","first-page":"463","article-title":"CD30 antigen in embryonal carcinoma and embryogenesis and release of the soluble molecule","volume":"146","author":"Latza","year":"1995","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.11.009_bib0180","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/modpathol.3800749","article-title":"D2-40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: a comparative immunohistochemical study with KIT (CD117) and CD30","volume":"20","author":"Lau","year":"2007","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.11.009_bib0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/002215540205000216","article-title":"CD30 and CD117 (c-kit) used in combination are useful for distinguishing embryonal carcinoma from seminoma","volume":"50","author":"Leroy","year":"2002","journal-title":"J. Histochem. Cytochem."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.11.009_bib0190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/PAS.0b013e318200cfd5","article-title":"Epithelioid inflammatory myofibroblastic sarcoma: an aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK","volume":"35","author":"Mari\u00f1o-Enr\u00edquez","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"8","key":"10.1016\/j.critrevonc.2016.11.009_bib0195","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/1097-0142(19901015)66:8<1732::AID-CNCR2820660815>3.0.CO;2-5","article-title":"Expression of Ki-1 antigen (CD30) in mesenchymal tumors","volume":"66","author":"Mechtersheimer","year":"1990","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.11.009_bib0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1001\/jamadermatol.2014.1629","article-title":"Brentuximab as a treatment for CD30+ mycosis fungoides and Sezary syndrome","volume":"151","author":"Mehra","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.11.009_bib0205","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2559.2004.02007.x","article-title":"Nasopharyngeal carcinoma mimicking large-cell anaplastic lymphoma","volume":"46","author":"Menasce","year":"2005","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2016.11.009_bib0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2012.12.008","article-title":"CD30-positive cutaneous T-cell lymphoma and response to Brentuximab Vedotin: 2 illustrative cases","volume":"13","author":"Mody","year":"2013","journal-title":"Clin. Lymph. Myeloma Leuk."},{"issue":"1\u20133","key":"10.1016\/j.critrevonc.2016.11.009_bib0215","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12026-013-8464-1","article-title":"CD30: from basic research to cancer therapy","volume":"57","author":"Muta","year":"2013","journal-title":"Immunol. Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.11.009_bib0220","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/cas.12435","article-title":"Phase I\/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma","volume":"105","author":"Ogura","year":"2014","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.11.009_bib0225","first-page":"446","article-title":"Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma","volume":"133","author":"Pallesen","year":"1988","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2016.11.009_bib0230","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2340\/00015555-1874","article-title":"Complete remission of refractory, ulcerated, primary cutaneous CD30+ anaplastic large cell lymphoma following brentuximab vedotin therapy","volume":"95","author":"Patsinakidis","year":"2015","journal-title":"Acta Derm. Venereol."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.11.009_bib0235","first-page":"903","article-title":"Ber-H2 (CD30) immunohistochemical staining in malignant melanoma","volume":"12","author":"Polski","year":"1999","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2016.11.009_bib0240","first-page":"782","article-title":"Activity of rituximab-bendamustine (RB) in sequence with brentuximab vedotin (adcetris TM, BV) in gray zone lymphoma (GZL) between hodgkins lymphoma (HL) and diffuse large B cell lymphoma (DLBCL)","volume":"35","author":"Ponugupati","year":"2012","journal-title":"J. Immunother."},{"issue":"18","key":"10.1016\/j.critrevonc.2016.11.009_bib0245","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2016.11.009_bib0250","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.13337","article-title":"Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression","volume":"172","author":"Saintes","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0255","first-page":"62","article-title":"Brentuximab vedotin (SGN 35): prolonged remission in a teen-ager with multiply relapsed anaplastic large cell lymphoma","volume":"159","author":"Sampson","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.11.009_bib0260","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood.V74.5.1678.1678","article-title":"BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope","volume":"74","author":"Schwarting","year":"1989","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.critrevonc.2016.11.009_bib0265","first-page":"[15]","article-title":"CD30 expression in nonlymphomatous malignancies","volume":"30","author":"Sharman","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.11.009_bib0270","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ijc.2910300411","article-title":"Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population","volume":"30","author":"Stein","year":"1982","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2016.11.009_bib0275","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0046-8177(98)90284-2","article-title":"Germ cell tumors of the mediastinum and testis: a comparative immunohistochemical study of 120 cases","volume":"29","author":"Suster","year":"1998","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2016.11.009_bib0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2016.02.007","article-title":"Role of maintenance therapy following high-Dose chemotherapy and autologous hematopoietic cell transplantation in aggressive lymphomas: a systematic review","author":"Taverna","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.11.009_bib0285","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1066896908318743","article-title":"Metastatic hepatocellular carcinoma of skin diagnosed with hepatocyte paraffin 1 and a-fetoprotein immunostainings","volume":"18","author":"Terada","year":"2010","journal-title":"Int. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2016.11.009_bib0290","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/DAD.0b013e31817330ff","article-title":"Cutaneous CD30-positive epithelioid angiosarcoma following breast-conserving therapy and irradiation: a potential diagnostic pitfall","volume":"30","author":"Weed","year":"2008","journal-title":"Am. J. Dermatopathol."},{"issue":"21","key":"10.1016\/j.critrevonc.2016.11.009_bib0295","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1745.1745","article-title":"Brentuximab vedotin in combination with RCHOP as front-line therapy in patients with DLBCL: interim results from a phase 2 study","volume":"124","author":"Yasenchak","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.critrevonc.2016.11.009_bib0300","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.critrevonc.2016.11.009_bib0305","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816303262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816303262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:31:53Z","timestamp":1692577913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816303262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":61,"alternative-id":["S1040842816303262"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.11.009","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}